Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$49.86 USD
+1.93 (4.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Apellis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 397 | 75 | 67 | 251 | 0 |
Cost Of Goods | 59 | 6 | 80 | 25 | 0 |
Gross Profit | 338 | 70 | -14 | 226 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 855 | 664 | 523 | 439 | 288 |
Income After Depreciation & Amortization | -517 | -595 | -536 | -214 | -288 |
Non-Operating Income | 20 | -24 | -196 | -99 | -11 |
Interest Expense | 30 | 33 | 13 | 30 | 5 |
Pretax Income | -527 | -652 | -746 | -343 | -305 |
Income Taxes | 2 | 1 | 0 | 2 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -529 | -652 | -746 | -345 | -305 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -529 | -652 | -746 | -345 | -305 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -489 | -593 | -534 | -198 | -285 |
Depreciation & Amortization (Cash Flow) | 28 | 2 | 2 | 16 | 3 |
Income After Depreciation & Amortization | -517 | -595 | -536 | -214 | -288 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 118.68 | 106.11 | 84.42 | 75.16 | 62.23 |
Diluted EPS Before Non-Recurring Items | -4.45 | -6.15 | -8.84 | -4.59 | -4.64 |
Diluted Net EPS (GAAP) | -4.45 | -6.15 | -8.84 | -4.59 | -4.90 |
Fiscal Year end for Apellis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 146.38 | 110.40 | 94.97 | 44.85 |
Cost Of Goods | NA | 19.91 | 22.41 | 8.38 | 7.81 |
Gross Profit | NA | 126.47 | 87.99 | 86.59 | 37.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 210.98 | 225.07 | 207.03 | 212.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -84.51 | -137.08 | -120.44 | -175.08 |
Non-Operating Income | NA | 4.77 | 4.39 | 5.94 | 5.12 |
Interest Expense | NA | 7.40 | 7.31 | 7.34 | 7.53 |
Pretax Income | NA | -87.15 | -140.00 | -121.84 | -177.50 |
Income Taxes | NA | 1.42 | 0.23 | 0.19 | 0.28 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -88.58 | -140.24 | -122.04 | -177.78 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -88.58 | -140.24 | -122.04 | -177.78 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 121.23 | 120.29 | 119.32 | 113.87 |
Diluted EPS Before Non-Recurring Items | NA | -0.73 | -1.17 | -1.02 | -1.56 |
Diluted Net EPS (GAAP) | NA | -0.70 | -1.17 | -1.02 | -1.56 |